Annual report pursuant to Section 13 and 15(d)

Acquisition - Schedule of Allocation of Purchase Price (Details)

v3.8.0.1
Acquisition - Schedule of Allocation of Purchase Price (Details) - USD ($)
Nov. 17, 2017
Dec. 31, 2017
Dec. 31, 2016
Fair value of liabilities assumed:      
Goodwill   $ 14,292,282 $ 0
TRx      
Current assets:      
Cash and cash equivalents $ 11,068    
Accounts receivable, net 2,872,545    
Inventory 495,777    
Prepaid expenses and other current assets 134,281    
Identifiable intangible assets      
Identifiable intangible assets 18,068,000    
Total assets acquired 21,581,671    
Fair value of liabilities assumed:      
Accounts payable 192,706    
Accrued expenses and other current liabilities 4,850,422    
Deferred tax liability 839,773    
Total liabilities assumed 5,882,901    
Total identifiable net assets 15,698,770    
Fair value of consideration transferred 29,991,052    
Goodwill 14,292,282    
PAI Sales & Marketing Agreement | TRx      
Identifiable intangible assets      
Identifiable intangible assets 2,334,000    
Metafolin | Acquired product marketing rights | TRx      
Identifiable intangible assets      
Identifiable intangible assets 10,465,000    
Millipred | Acquired product marketing rights | TRx      
Identifiable intangible assets      
Identifiable intangible assets 4,714,000    
Ulesfia | Acquired product marketing rights | TRx      
Identifiable intangible assets      
Identifiable intangible assets $ 555,000